← Eichor
Condition: Transfusion Dependent Thalassemia Patients Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Transfusion Dependent Thalassemia Patients

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploid
Phase 2 · 5 location(s) · Rongrong Liu · NCT06657391Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Phase 2 · 8 location(s) · Rongrong Liu · NCT07338344the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
EARLY_Phase 1 · 1 location(s) · Shenzhen Hemogen · NCT05864170T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Phase 1/Phase 2 · 1 location(s) · Paul Szabolcs · NCT03653338A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Phase 2 · 5 location(s) · Kind Pharmaceuticals LLC · NCT06302491the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
EARLY_Phase 1 · 1 location(s) · Shenzhen Hemogen · NCT05851105Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTD
NA · 1 location(s) · Centre Hospitalier Metropole Savoie · NCT07207577Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
NA · 1 location(s) · Shanghai BDgene Co., Ltd. · NCT05773729Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06219239A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
Phase 1 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06772766Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
NA · 1 location(s) · Shanghai BDgene Co., Ltd. · NCT05776173Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Phase 2 · 1 location(s) · Paul Szabolcs · NCT01962415A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
Phase 1 · 3 location(s) · Shanghai BDgene Co., Ltd. · NCT06465550Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
Phase 1 · 3 location(s) · Shenzhen Hemogen · NCT06655662
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.